$1.63
16.43%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
US45773H2013
Symbol
INO

Inovio Pharmaceuticals, Inc. Stock price

$1.63
+0.63 63.00% 1M
+0.41 33.61% 6M
-0.11 6.32% YTD
-0.35 17.68% 1Y
-3.52 68.34% 3Y
-87.17 98.16% 5Y
-94.61 98.31% 10Y
-149.57 98.92% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
+0.23 16.43%
ISIN
US45773H2013
Symbol
INO
Industry

Is Inovio Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$262.2m
Enterprise Value
$225.6m
Net debt
positive
Cash
$36.7m
Shares outstanding
82.3m
Valuation
P/E
negative
P/S | estimate
- | 389.4
EV/Sales | estimate
- | 335.0
EV/FCF | ex SBC
negative | negative
P/B
60.0
Financial Health
Equity Ratio
32.4%
Return on Equity
-352.5%
ROCE
-837.0%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$3.0m | -
SBC as % of FCF
-
SBC Growth 1Y
-35.6%
Share Count Growth 1Y
124.2%
Shareholder Yield
-
Financials
Revenue | estimate
$0.0 | $673.3k
EBITDA
$-77.9m
EBIT
$-79.3m
Net Income
$-67.4m
Free Cash Flow | ex SBC
$-80.8m | $-83.8m
Growth
Revenue | estimate
-100.0% | 861.9%
EBITDA
17.0%
EBIT
17.0%
Net Income
23.0%
Free Cash Flow
14.8%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.8
FCF per Share
$-1.0
Short interest
22.1%
Employees
112
Rev per Employee
$0.0

Inovio Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

Buy
71%
Hold
29%

Inovio Pharmaceuticals, Inc. Events

Past Events
NOV
10
Q3 2026 Earnings Call
7 days ago
NOV
2
Special Call - Inovio Pharmaceuticals, Inc.
15 days ago
SEP
11
H.C. Wainwright 28th Annual Global Investment Conference
2 months ago
SEP
9
12th Annual Cantor Fitzgerald Global Healthcare Conference
2 months ago
AUG
12
Q2 2026 Earnings Call
3 months ago
JUN
4
Jefferies Global Healthcare Conference 2026
6 months ago
MAY
13
Q1 2026 Earnings Call
6 months ago
MAR
12
Q4 2025 Earnings Call
8 months ago
MAR
10
The Citizens Life Sciences Conference 2026
8 months ago
FEB
25
Oppenheimer 36th Annual Healthcare Life Sciences Conference
9 months ago
DEC
2
Piper Sandler 37th Annual Healthcare Conference
12 months ago
NOV
10
Q3 2025 Earnings Call
about one year ago

Financial data from Inovio Pharmaceuticals, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
9% 9%
-
- Research and Development Expense 48 48
22% 22%
-
-78 -78
17% 17%
-
- Depreciation and Amortization 1.33 1.33
15% 15%
-
EBIT (Operating Income) EBIT -79 -79
17% 17%
-
Net Profit -67 -67
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Inovio Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inovio Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
●
7 days ago
VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP) VOCERYQ expected to be available to order and ship in approximately 60 days from the approval date with full commercial launch in first quarter 2027 VOCERYQ rep...
Neutral
PRNewsWire
●
12 days ago
PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 58,747,235 shares of its common stock at a public offering pri...
More Inovio Pharmaceuticals, Inc. News

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Dr. Shea
Employees 112
Founded 1983
Website www.inovio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today